Just as rock climbers use gritstones to scale massive peaks, the San Francisco-based startup Gritstone Oncology raised $102m for the development of neoantigen-containing cancer vaccines that may help the immune system mount a targeted attack against tumors.
Gritstone co-founder, president and CEO Andrew Allen – the rock climber responsible for the startup's name – is building the...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

